A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Repeat Oral Doses of MT-501 in Healthy Volunteers
Latest Information Update: 15 Jan 2025
Price :
$35 *
At a glance
- Drugs MT 501 (Primary)
- Indications Unspecified
- Focus Adverse reactions; First in man
- Sponsors Mirador Therapeutics
- 15 Jan 2025 New trial record